AstraZeneca reached a drug‑pricing agreement with the White House, following earlier deals under the administration’s pricing initiative. Reports indicated the pact mirrors discounts other manufacturers agreed to under the administration’s negotiating approach. Coverage from multiple outlets framed the arrangement as the second high‑profile pricing deal announced by the White House. The engagement is presented as part of an administration effort to secure similar pricing terms across major portfolios. The agreement underscores heightened executive‑branch involvement in drug pricing and may set a commercial precedent for future negotiations between the government and large pharma.